Access to cancer medications in low- and middle-income countries

被引：0
作者：
Gilberto de Lima Lopes
Jonas A. de Souza
Carlos Barrios
机构：
[1] The Johns Hopkins Singapore International Medical Centre of the Johns Hopkins University School of Medicine,Department of Medicine
[2] University of Chicago,undefined
[3] School of Medicine,undefined
[4] Porto Alegre,undefined
[5] Rio Grande do Sul,undefined
[6] Brazil,undefined
来源：
Nature Reviews Clinical Oncology | 2013年 / 10卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
For patients in low and middle-income countries (LMICs), many of the advances in medical oncology enjoyed in the developed world are nothing but an aspiration for the future. However, as Gilberto Lopes Jr and colleagues describe, LMICS are using generic and biosimilar drugs, expanding participation in clinical trials, implementing universal health-care schemes, using compulsory licensing schemes and increasing public–private partnerships to increase access to cancer medications for their citizens.
引用
收藏
页码：314 / 322
页数：8
相关论文
共 45 条
[1]  
Mathers CD(2006)Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med. 3 e442-2065
[2]  
Loncar D(2010)Declining death rates reflect progress against cancer PLoS ONE 5 e9584-214
[3]  
Jemal A(2011)Bending the cost curve in cancer care N. Engl. J. Med. 364 2060-2526
[4]  
Ward E(2010)How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 203-38
[5]  
Thun M(2008)Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis JAMA 300 2514-428
[6]  
Smith T(2011)Physician perceptions about generic drugs Ann. Pharmacother. 45 31-25
[7]  
Hillner BE(2011)Impact of switching therapy from imatinib mesylate to generic copy of imatinib on hematologic response in patients with chronic phase chronic myeloid leukemia: single center study [abstract 1219] Haematologica 96 a1219-99
[8]  
Paul SM(2012)Can next-generation antibodies offset biosimilar competition? Nat. Rev. Drug Discov. 11 426-97
[9]  
Kesselheim AS(1999)AIDS, essential medicines, and compulsory licensing J. Int. Assoc. Physicians AIDS Care 5 24-221
[10]  
Shrank WS(2012)Impact of the introduction of government use licenses on the drug expenditure on seven medicines in Thailand Value Health 15 95-349
12345